Eli Lilly's $7B Kelonia acquisition screams desperation louder than their 45.6% revenue growth screams success. Think about it: when you're posting monster growth and still dropping billions on external assets, your organic machine is broken. That glossy 31.7% net margin becomes meaningless when you're overpaying for someone else's innovation because your own pipeline is running dry. This isn't growth strategy—it's growth panic. Big Pharma's quality premium is about to collapse.

Research these companies